Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

Fri, 10th May 2019 09:36

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed in the period.

For the six months to the end of March, the trust's net asset value negative return was 3.0%, compared to the 2.3% negative return by the MSCI ACWI/Healthcare Index in sterling terms, with dividends reinvested.

Net asset value per share as at March 31 was 233.53 pence, up from 183.00p the same date the year before, but down from 241.91p at the end of September.

Polar Capital's share price at the end of March was 216.00p, reflecting a discount to net asset value of 7.5%, widened from 6.1% the year before.

Shares in Polar Capital Global Healthcare were down 1.0% on the day Friday at 203.50 pence, having fallen 5.8% since the period-end.

The trust said that the overall healthcare market "modestly underperformed", with major sell-offs in October and December due to trade friction, slowing global growth, as well as political uncertainties.

Detractors within the trust's portfolio includes Diurnal Group PLC, which reported that its congenital adrenal hyperplasia treatment product Chronocort failed to meet its primary objective in its phase three trial.

Another detractor was Consort Medical PLC, due to delays in some of its customer projects.

However, stocks that performed well were Merck & Co Inc, with strong momentum in its immuno-oncology and vaccines businesses, and Renalytix AI PLC, due to progress in the development of its AI-enabled product for treating kidney diseases.

"While backward looking, the temperamental, almost nervous nature of the market further underpins our view that large-cap healthcare companies should be a relatively attractive place to invest in the near to medium term," Polar Capital Global Healthcare said.

"With technology at the fore, we continue to believe we can find companies within our investment universe that are capable of delivering mid to high single-digit, organic, top-line growth, operating leverage as well as high single to low double-digit total shareholder returns," the trust added.

More News
25 Jul 2018 09:39

IP Group Swings To Loss In First-Half On Reduction In Portfolio Gains

LONDON (Alliance News) - IP Group PLC on Wednesday said it saw a swing to loss in the first half of 2018 despite an improvement in its portfolio valuation.The intellectual property-based to

Read more
18 Jun 2018 16:22

Abcam Appoints Former Celltech CFO As Non-Executive Chairman

LONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at

Read more
3 Apr 2018 16:19

Diurnal To Raise GBP10.5 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Diurnal Group PLC said on Tuesday that it intends to raise GBP10.5 million through the placing of different types of shares.The

Read more
20 Mar 2018 18:28

Diurnal Nets GBP500,000 From Broker Option Exercise (ALLISS)

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Tuesday said that it has received a letter of notice to exercise the broker option in respect of 263,157 in

Read more
12 Mar 2018 13:51

UPDATE: Diurnal Prepares For First Revenue As Appoints Trial Partner

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC on Monday appointed a clinical trial services provider for its Chronocort treatment, as it posted a widened loss

Read more
12 Mar 2018 10:18

Diurnal Interim Loss Widens On Cost Rise As Prepares For First Revenue

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Monday its interim loss widened amid a rise in research and administrative expenses, as it prepares to its

Read more
12 Mar 2018 05:17

UK Stocks-Factors to watch on March 12

March 12 (Reuters) - Britain's FTSE 100 index is seen opening up 8 points higher at 7,233 on Monday, according to financial bookmakers. * GKN-MELROSE: GKN has struck a deal

Read more
25 Jan 2017 09:31

Diurnal Agrees Two Deals With UDG Healthcare Ahead Of Infacort Launch

Read more
17 Jan 2017 15:43

DIRECTOR DEALINGS: Diurnal Non-Executive Ups Interest

Read more
16 Jan 2017 15:08

Director dealings: Diurnal trio dip in after EMA submission in December

(ShareCast News) - A trio of Diurnal Group directors bought shares in the hormone disease specialist, which remain little higher than the low reached late last year. Chairman Peter Allen bought 40,000 shares at 105p and non-executive directors Sam Williams and John Goddard bought 9,248 each at a pri

Read more
12 Jan 2017 09:04

Diurnal Hires Outgoing Mereo BioPharma Finance Chief Bungay

Read more
20 Dec 2016 12:23

Diurnal Submits European Marketing Application For Infacort

Read more
21 Nov 2016 09:32

Diurnal Doses First Testosterone Replacement Therapy Trial Patients

Read more
5 Oct 2016 15:09

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
11 Jul 2016 08:00

Diurnal and IP Group eye 2017 launch for childhood hormonal treatment

(ShareCast News) - Diurnal Group, 45%-owned by university spin-out specialist IP Group, has produced positive clinical trial results for its treatment for a rare hormonal disease in young children. A European Phase III study for AIM-quoted Diurnal's Infacort treatment for paediatric Adrenal Insuffic

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.